You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDeslanoside
Accession NumberDB01078  (APRD00909)
TypeSmall Molecule
GroupsApproved
DescriptionDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. [PubChem]
Structure
Thumb
Synonyms
(3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
3-[(O-beta-D-Glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
Deacetyllanatoside C
Desacetyllanatoside C
Deslanosido
Deslanosidum
Glucodigoxin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cedilanid-dNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYGY317RK75
CAS number17598-65-1
WeightAverage: 943.0791
Monoisotopic: 942.482430186
Chemical FormulaC47H74O19
InChI KeyOBATZBGFDSVCJD-LALPQLPRSA-N
InChI
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-11,16-dihydroxy-5-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
C[[email protected]]1O[[email protected]](C[[email protected]](O)[C@@H]1O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[C@@H]3O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]3O)[C@@H](C)O2)[C@@H](C)O1)O[[email protected]]1CC[C@@]2(C)[[email protected]](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[[email protected]](CC[C@]32O)C2=CC(=O)OC2)C1
Pharmacology
IndicationFor the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.
Structured Indications Not Available
PharmacodynamicsDeslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism of actionDeslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1Proteinyes
inhibitor
HumanP05023 details
Related Articles
AbsorptionLittle absorption from the gastrointestinal tract (40%).
Volume of distributionNot Available
Protein binding20%
MetabolismNot Available
Route of eliminationNot Available
Half life36 hours
ClearanceNot Available
ToxicitySymptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDeslanoside may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolDeslanoside may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideDeslanoside may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidDeslanoside may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidDeslanoside may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineDeslanoside may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental
8-azaguanineDeslanoside may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineDeslanoside may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneDeslanoside may decrease the cardiotoxic activities of Abiraterone.Approved
ABT-263Deslanoside may decrease the cardiotoxic activities of ABT-263.Investigational
AcebutololAcebutolol may increase the bradycardic activities of Deslanoside.Approved
AclarubicinDeslanoside may decrease the cardiotoxic activities of Aclarubicin.Investigational
ActeosideDeslanoside may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibDeslanoside may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneDeslanoside may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptDeslanoside may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinDeslanoside may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleDeslanoside may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AldesleukinDeslanoside may decrease the cardiotoxic activities of Aldesleukin.Approved
AlemtuzumabDeslanoside may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlfacalcidolAlfacalcidol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
AlitretinoinDeslanoside may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineDeslanoside may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.Experimental
AlprenololAlprenolol may increase the bradycardic activities of Deslanoside.Approved, Withdrawn
AltretamineDeslanoside may decrease the cardiotoxic activities of Altretamine.Approved
Amg 386Deslanoside may decrease the cardiotoxic activities of Amg 386.Investigational
AmikacinThe serum concentration of Deslanoside can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Amiloride.Approved
AminocamptothecinDeslanoside may decrease the cardiotoxic activities of Aminocamptothecin.Investigational
AminoglutethimideDeslanoside may decrease the cardiotoxic activities of Aminoglutethimide.Approved
Aminolevulinic acidDeslanoside may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Deslanoside can be increased when it is combined with Amodiaquine.Approved
AmonafideDeslanoside may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.Approved, Investigational
AmrubicinDeslanoside may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineDeslanoside may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideDeslanoside may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleDeslanoside may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveDeslanoside may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinDeslanoside may decrease the cardiotoxic activities of annamycin.Investigational
Aop200704Aop200704 may increase the bradycardic activities of Deslanoside.Investigational
AP 12009Deslanoside may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Deslanoside may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneDeslanoside may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Deslanoside can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Deslanoside can be decreased when it is combined with Arbekacin.Approved
ArotinololArotinolol may increase the bradycardic activities of Deslanoside.Approved
Arsenic trioxideDeslanoside may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
ASA404Deslanoside may decrease the cardiotoxic activities of ASA404.Investigational
AsparaginaseDeslanoside may decrease the cardiotoxic activities of Asparaginase.Approved
AT-101Deslanoside may decrease the cardiotoxic activities of AT-101.Investigational
AtenololAtenolol may increase the bradycardic activities of Deslanoside.Approved
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Deslanoside.Approved
AxitinibDeslanoside may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineDeslanoside may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineDeslanoside may decrease the cardiotoxic activities of Azathioprine.Approved
AZD2171Deslanoside may decrease the cardiotoxic activities of AZD2171.Investigational
Azd4547Deslanoside may decrease the cardiotoxic activities of Azd4547.Investigational
Azelaic AcidDeslanoside may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Deslanoside can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Deslanoside can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatDeslanoside may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Deslanoside.Experimental
BelinostatDeslanoside may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanDeslanoside may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineDeslanoside may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Deslanoside.Approved
BesifloxacinDeslanoside may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Deslanoside.Approved
Betulinic AcidDeslanoside may decrease the cardiotoxic activities of Betulinic Acid.Investigational
BevacizumabDeslanoside may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Deslanoside.Approved
BexaroteneDeslanoside may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
Bgj398Deslanoside may decrease the cardiotoxic activities of Bgj398.Investigational
BicalutamideDeslanoside may decrease the cardiotoxic activities of Bicalutamide.Approved
BisoprololBisoprolol may increase the bradycardic activities of Deslanoside.Approved
BizelesinDeslanoside may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinDeslanoside may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabDeslanoside may decrease the cardiotoxic activities of Blinatumomab.Approved
Bmn 673Deslanoside may decrease the cardiotoxic activities of Bmn 673.Investigational
BopindololBopindolol may increase the bradycardic activities of Deslanoside.Approved
BortezomibDeslanoside may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibDeslanoside may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinDeslanoside may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineDeslanoside may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Deslanoside may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Deslanoside may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Deslanoside.Investigational
BufuralolBufuralol may increase the bradycardic activities of Deslanoside.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside.Approved
BupranololBupranolol may increase the bradycardic activities of Deslanoside.Approved
BusulfanDeslanoside may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineDeslanoside may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelDeslanoside may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineDeslanoside may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibDeslanoside may decrease the cardiotoxic activities of Cabozantinib.Approved
CaiDeslanoside may decrease the cardiotoxic activities of Cai.Investigational
CalcidiolCalcidiol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
CalcipotriolDeslanoside may decrease the cardiotoxic activities of Calcipotriol.Approved
CalcitriolCalcitriol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
CalciumCalcium may increase the arrhythmogenic activities of Deslanoside.Nutraceutical
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium carbonateCalcium carbonate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium citrateCalcium citrate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Deslanoside.Approved, Vet Approved
CamptothecinDeslanoside may decrease the cardiotoxic activities of Camptothecin.Experimental
CapecitabineDeslanoside may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Deslanoside can be increased when it is combined with Carbimazole.Approved
CarbomycinThe serum concentration of Deslanoside can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinDeslanoside may decrease the cardiotoxic activities of Carboplatin.Approved
CarfilzomibDeslanoside may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurDeslanoside may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineDeslanoside may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Deslanoside.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Deslanoside.Approved, Investigational
CatumaxomabDeslanoside may decrease the cardiotoxic activities of Catumaxomab.Investigational
CB1954Deslanoside may decrease the cardiotoxic activities of CB1954.Experimental
CediranibDeslanoside may decrease the cardiotoxic activities of Cediranib.Investigational
CelecoxibDeslanoside may decrease the cardiotoxic activities of Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
CeritinibDeslanoside may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabDeslanoside may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilDeslanoside may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Deslanoside can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.Approved, Vet Approved
ChlorotrianiseneDeslanoside may decrease the cardiotoxic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside.Approved
CholecalciferolCholecalciferol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinDeslanoside may decrease the cardiotoxic activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinDeslanoside may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Deslanoside.Approved
CisplatinDeslanoside may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineDeslanoside may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Deslanoside can be increased when it is combined with Clarithromycin.Approved
ClofarabineDeslanoside may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
clorarabineDeslanoside may decrease the cardiotoxic activities of clorarabine.Investigational
ColchicineDeslanoside may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CordycepinDeslanoside may decrease the cardiotoxic activities of Cordycepin.Investigational
CrenolanibDeslanoside may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibDeslanoside may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminDeslanoside may decrease the cardiotoxic activities of Curcumin.Investigational
CyclophosphamideDeslanoside may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateDeslanoside may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineDeslanoside may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibDeslanoside may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineDeslanoside may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinDeslanoside may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabDeslanoside may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibDeslanoside may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinDeslanoside may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Deslanoside.Approved
DecitabineDeslanoside may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
Denileukin diftitoxDeslanoside may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinDeslanoside may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneDeslanoside may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneDeslanoside may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DienogestDeslanoside may decrease the cardiotoxic activities of Dienogest.Approved
DiethylstilbestrolDeslanoside may decrease the cardiotoxic activities of Diethylstilbestrol.Approved
DihydrostreptomycinThe serum concentration of Deslanoside can be decreased when it is combined with Dihydrostreptomycin.Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Deslanoside.Approved
DiindolylmethaneDeslanoside may decrease the cardiotoxic activities of Diindolylmethane.Investigational
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DinutuximabDeslanoside may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelDeslanoside may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Deslanoside.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Deslanoside.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Deslanoside.Approved
DoxifluridineDeslanoside may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinDeslanoside may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
EcabetDeslanoside may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
efaproxiralDeslanoside may decrease the cardiotoxic activities of efaproxiral.Investigational
EflornithineDeslanoside may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Deslanoside may decrease the cardiotoxic activities of EG009.Investigational
ElsamitrucinDeslanoside may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinDeslanoside may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinDeslanoside may decrease the cardiotoxic activities of Enoxacin.Approved
EnrofloxacinDeslanoside may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatDeslanoside may decrease the cardiotoxic activities of Entinostat.Investigational
EpirubicinDeslanoside may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Eplerenone.Approved
EpofolateDeslanoside may decrease the cardiotoxic activities of Epofolate.Investigational
Epothilone BDeslanoside may decrease the cardiotoxic activities of Epothilone B.Experimental, Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
EribulinDeslanoside may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibDeslanoside may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Deslanoside can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Deslanoside.Approved
EstramustineDeslanoside may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.Approved
EtanidazoleDeslanoside may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilDeslanoside may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateDeslanoside may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoposideDeslanoside may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusDeslanoside may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanDeslanoside may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneDeslanoside may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindDeslanoside may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideDeslanoside may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineDeslanoside may decrease the cardiotoxic activities of Fiacitabine.Investigational
FlavopiridolDeslanoside may decrease the cardiotoxic activities of Flavopiridol.Experimental, Investigational
FleroxacinDeslanoside may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineDeslanoside may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineDeslanoside may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineDeslanoside may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilDeslanoside may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideDeslanoside may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneDeslanoside may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinDeslanoside may decrease the cardiotoxic activities of Formycin.Experimental
FotemustineDeslanoside may decrease the cardiotoxic activities of Fotemustine.Experimental
FramycetinThe serum concentration of Deslanoside can be decreased when it is combined with Framycetin.Approved
FulvestrantDeslanoside may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinDeslanoside may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside.Approved, Vet Approved
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Deslanoside.Approved
Gallium nitrateDeslanoside may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinDeslanoside may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinDeslanoside may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibDeslanoside may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinDeslanoside may decrease the cardiotoxic activities of Geldanamycin.Experimental
GemcitabineDeslanoside may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinDeslanoside may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinDeslanoside may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GeneticinThe serum concentration of Deslanoside can be decreased when it is combined with Geneticin.Experimental
GenisteinDeslanoside may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Deslanoside can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Deslanoside can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CDeslanoside may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinDeslanoside may decrease the cardiotoxic activities of Goserelin.Approved
GrepafloxacinDeslanoside may decrease the cardiotoxic activities of Grepafloxacin.Withdrawn
GusperimusDeslanoside may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinDeslanoside may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneDeslanoside may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolDeslanoside may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside.Approved
HydroxychloroquineThe serum concentration of Deslanoside can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateDeslanoside may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaDeslanoside may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Deslanoside can be decreased when it is combined with Hygromycin B.Vet Approved
IbrutinibDeslanoside may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinDeslanoside may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibDeslanoside may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideDeslanoside may decrease the cardiotoxic activities of Ifosfamide.Approved
Il 4Deslanoside may decrease the cardiotoxic activities of Il 4.Investigational
ImatinibDeslanoside may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodDeslanoside may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.Approved
IndenololIndenolol may increase the bradycardic activities of Deslanoside.Withdrawn
IndirubinDeslanoside may decrease the cardiotoxic activities of Indirubin.Investigational
INNO-206The serum concentration of Deslanoside can be decreased when it is combined with INNO-206.Investigational
Interferon beta-1aDeslanoside may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
Interferon beta-1bDeslanoside may decrease the cardiotoxic activities of Interferon beta-1b.Approved
IobenguaneDeslanoside may decrease the cardiotoxic activities of Iobenguane.Approved
IpilimumabDeslanoside may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanDeslanoside may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenDeslanoside may decrease the cardiotoxic activities of Irofulven.Investigational
ItraconazoleThe serum concentration of Deslanoside can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneDeslanoside may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibDeslanoside may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Deslanoside can be increased when it is combined with Josamycin.Approved
KanamycinThe serum concentration of Deslanoside can be decreased when it is combined with Kanamycin.Approved, Vet Approved
KaolinThe serum concentration of Deslanoside can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Deslanoside can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Deslanoside may decrease the cardiotoxic activities of KOS-1584.Investigational
L-alanosineDeslanoside may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Deslanoside.Approved
LanreotideDeslanoside may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibDeslanoside may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LeflunomideDeslanoside may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideDeslanoside may decrease the cardiotoxic activities of Lenalidomide.Approved
LenvatinibDeslanoside may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleDeslanoside may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideDeslanoside may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Deslanoside.Approved
LevofloxacinDeslanoside may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleDeslanoside may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Deslanoside.Approved
LomefloxacinDeslanoside may decrease the cardiotoxic activities of Lomefloxacin.Approved
LomustineDeslanoside may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineDeslanoside may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
Ly2801653Deslanoside may decrease the cardiotoxic activities of Ly2801653.Investigational
LycopeneDeslanoside may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideDeslanoside may decrease the cardiotoxic activities of Mafosfamide.Investigational
MasitinibDeslanoside may decrease the cardiotoxic activities of Masitinib.Vet Approved
MasoprocolDeslanoside may decrease the cardiotoxic activities of Masoprocol.Approved
MaxacalcitolDeslanoside may decrease the cardiotoxic activities of Maxacalcitol.Approved
MDX-1106Deslanoside may decrease the cardiotoxic activities of MDX-1106.Investigational
MebendazoleDeslanoside may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineDeslanoside may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneDeslanoside may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateDeslanoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateDeslanoside may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanDeslanoside may decrease the cardiotoxic activities of Melphalan.Approved
MequinolDeslanoside may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineDeslanoside may decrease the cardiotoxic activities of Mercaptopurine.Approved
MesalazineThe serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Deslanoside can be increased when it is combined with Methimazole.Approved
MethotrexateDeslanoside may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.Approved
Methyl aminolevulinateDeslanoside may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneDeslanoside may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethyltestosteroneDeslanoside may decrease the cardiotoxic activities of Methyltestosterone.Approved
MetipranololMetipranolol may increase the bradycardic activities of Deslanoside.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Deslanoside.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Deslanoside.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.Approved
MetoprololMetoprolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
MetrizamideThe serum concentration of Deslanoside can be decreased when it is combined with Metrizamide.Approved
MGI-114Deslanoside may decrease the cardiotoxic activities of MGI-114.Investigational
MidodrineDeslanoside may increase the bradycardic activities of Midodrine.Approved
MidostaurinDeslanoside may decrease the cardiotoxic activities of Midostaurin.Investigational
MiltefosineDeslanoside may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleDeslanoside may decrease the cardiotoxic activities of Misonidazole.Investigational
MitoguazoneDeslanoside may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolDeslanoside may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinDeslanoside may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneDeslanoside may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneDeslanoside may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Deslanoside.Approved
MizoribineDeslanoside may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Deslanoside may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimDeslanoside may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumDeslanoside may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinDeslanoside may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolic acidDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadololNadolol may increase the bradycardic activities of Deslanoside.Approved
Nalidixic AcidDeslanoside may decrease the cardiotoxic activities of Nalidixic Acid.Approved
NamitecanDeslanoside may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxDeslanoside may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Deslanoside can be decreased when it is combined with Neamine.Experimental
NecitumumabDeslanoside may decrease the cardiotoxic activities of Necitumumab.Approved
NelarabineDeslanoside may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Deslanoside can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Deslanoside.Investigational
NetilmicinThe serum concentration of Deslanoside can be decreased when it is combined with Netilmicin.Approved
NiguldipineDeslanoside may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibDeslanoside may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideDeslanoside may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineDeslanoside may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibDeslanoside may decrease the cardiotoxic activities of Nintedanib.Approved
NivolumabDeslanoside may decrease the cardiotoxic activities of Nivolumab.Approved
Nk012Deslanoside may decrease the cardiotoxic activities of Nk012.Investigational
nocodazoleDeslanoside may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedDeslanoside may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinDeslanoside may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabDeslanoside may decrease the cardiotoxic activities of Obinutuzumab.Approved
OctreotideDeslanoside may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabDeslanoside may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinDeslanoside may decrease the cardiotoxic activities of Ofloxacin.Approved
OlaparibDeslanoside may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Deslanoside can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.Approved
Omacetaxine mepesuccinateDeslanoside may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OprelvekinDeslanoside may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibDeslanoside may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinDeslanoside may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
OxprenololOxprenolol may increase the bradycardic activities of Deslanoside.Approved
PaclitaxelDeslanoside may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
PalbociclibDeslanoside may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideDeslanoside may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateDeslanoside may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Deslanoside.Approved
PanitumumabDeslanoside may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatDeslanoside may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Deslanoside.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Deslanoside.Approved, Investigational
ParomomycinThe serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.Approved, Investigational
PARP inhibitorDeslanoside may decrease the cardiotoxic activities of PARP inhibitor.Investigational
PazopanibDeslanoside may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinDeslanoside may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinDeslanoside may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseDeslanoside may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabDeslanoside may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedDeslanoside may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
PenclomedineDeslanoside may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinDeslanoside may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabDeslanoside may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenylacetic acidDeslanoside may decrease the cardiotoxic activities of Phenylacetic acid.Approved
PindololPindolol may increase the bradycardic activities of Deslanoside.Approved
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
PipobromanDeslanoside may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinDeslanoside may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.Experimental
PirfenidoneDeslanoside may decrease the cardiotoxic activities of Pirfenidone.Investigational
PirlindoleDeslanoside may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneDeslanoside may decrease the cardiotoxic activities of Pixantrone.Investigational
PlevitrexedDeslanoside may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinDeslanoside may decrease the cardiotoxic activities of Plicamycin.Approved, Withdrawn
PodofiloxDeslanoside may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinDeslanoside may decrease the cardiotoxic activities of Podophyllin.Approved
polyacrylic acidDeslanoside may decrease the cardiotoxic activities of polyacrylic acid.Investigational
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Deslanoside.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Deslanoside.Approved
PomalidomideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibDeslanoside may decrease the cardiotoxic activities of Ponatinib.Approved
PorfimerDeslanoside may decrease the cardiotoxic activities of Porfimer.Approved, Investigational
porfiromycinDeslanoside may decrease the cardiotoxic activities of porfiromycin.Investigational
PractololPractolol may increase the bradycardic activities of Deslanoside.Approved
PralatrexateDeslanoside may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineDeslanoside may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneDeslanoside may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneDeslanoside may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Deslanoside can be increased when it is combined with Primaquine.Approved
ProcarbazineDeslanoside may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Deslanoside can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
PropylthiouracilThe serum concentration of Deslanoside can be increased when it is combined with Propylthiouracil.Approved
Purine RibosideDeslanoside may decrease the cardiotoxic activities of Purine Riboside.Experimental
PuromycinDeslanoside may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Deslanoside.Approved, Vet Approved
PyrazoloacridineDeslanoside may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
Qlt091001Deslanoside may decrease the cardiotoxic activities of Qlt091001.Investigational
QuinacrineDeslanoside may decrease the cardiotoxic activities of Quinacrine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Deslanoside.Approved
QuinidineThe serum concentration of Deslanoside can be increased when it is combined with Quinidine.Approved
Radium Ra 223 DichlorideDeslanoside may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedDeslanoside may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabDeslanoside may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabDeslanoside may decrease the cardiotoxic activities of Ranibizumab.Approved
RanpirnaseDeslanoside may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Deslanoside.Withdrawn
RegorafenibDeslanoside may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Deslanoside.Approved
ResveratrolDeslanoside may decrease the cardiotoxic activities of Resveratrol.Experimental, Investigational
Rhodamine 6GDeslanoside may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Deslanoside can be decreased when it is combined with Ribostamycin.Approved
RituximabDeslanoside may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Deslanoside.Approved
RomidepsinDeslanoside may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RomiplostimDeslanoside may decrease the cardiotoxic activities of Romiplostim.Approved
RoquinimexDeslanoside may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanDeslanoside may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibDeslanoside may decrease the cardiotoxic activities of Rucaparib.Investigational
RuxolitinibDeslanoside may decrease the cardiotoxic activities of Ruxolitinib.Approved
SalirasibDeslanoside may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibDeslanoside may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinDeslanoside may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibDeslanoside may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibDeslanoside may decrease the cardiotoxic activities of Semaxanib.Investigational
SeocalcitolDeslanoside may decrease the cardiotoxic activities of Seocalcitol.Experimental
SiltuximabDeslanoside may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusDeslanoside may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Deslanoside can be decreased when it is combined with Sisomicin.Investigational
Sodium phenylbutyrateDeslanoside may decrease the cardiotoxic activities of Sodium phenylbutyrate.Approved
SolithromycinThe serum concentration of Deslanoside can be increased when it is combined with Solithromycin.Investigational
SonidegibDeslanoside may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SonifilanDeslanoside may decrease the cardiotoxic activities of Sonifilan.Investigational
SorafenibDeslanoside may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Deslanoside.Approved
SP1049CThe serum concentration of Deslanoside can be decreased when it is combined with SP1049C.Investigational
SparfloxacinDeslanoside may decrease the cardiotoxic activities of Sparfloxacin.Approved
Sparfosic acidDeslanoside may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinDeslanoside may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Deslanoside can be decreased when it is combined with Spectinomycin.Approved, Vet Approved
SpiramycinThe serum concentration of Deslanoside can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone.Approved
squalamineDeslanoside may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Deslanoside may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Deslanoside can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinDeslanoside may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Deslanoside.Approved
SulfasalazineThe serum concentration of Deslanoside can be decreased when it is combined with Sulfasalazine.Approved
SulforaphaneDeslanoside may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacDeslanoside may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.Approved
SunitinibDeslanoside may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminDeslanoside may decrease the cardiotoxic activities of Suramin.Approved
SwainsonineDeslanoside may decrease the cardiotoxic activities of Swainsonine.Experimental
TalaporfinDeslanoside may decrease the cardiotoxic activities of Talaporfin.Investigational
TamoxifenDeslanoside may decrease the cardiotoxic activities of Tamoxifen.Approved
TegafurDeslanoside may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Deslanoside can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Deslanoside can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinDeslanoside may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinDeslanoside may decrease the cardiotoxic activities of Temoporfin.Approved
TemozolomideDeslanoside may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusDeslanoside may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideDeslanoside may decrease the cardiotoxic activities of Teniposide.Approved
TestolactoneDeslanoside may decrease the cardiotoxic activities of Testolactone.Approved
TetrathiomolybdateDeslanoside may decrease the cardiotoxic activities of Tetrathiomolybdate.Investigational
TezacitabineDeslanoside may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideDeslanoside may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaDeslanoside may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinDeslanoside may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiboloneDeslanoside may decrease the cardiotoxic activities of Tibolone.Approved
TimololTimolol may increase the bradycardic activities of Deslanoside.Approved
TioguanineDeslanoside may decrease the cardiotoxic activities of Tioguanine.Approved
TipifarnibDeslanoside may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineDeslanoside may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibDeslanoside may decrease the cardiotoxic activities of Tivozanib.Investigational
Tnp 470Deslanoside may decrease the cardiotoxic activities of Tnp 470.Investigational
TobramycinThe serum concentration of Deslanoside can be decreased when it is combined with Tobramycin.Approved, Investigational
TopotecanDeslanoside may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.Approved
ToremifeneDeslanoside may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabDeslanoside may decrease the cardiotoxic activities of Tositumomab.Approved
TrabectedinDeslanoside may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibDeslanoside may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabDeslanoside may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineDeslanoside may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TreosulfanDeslanoside may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarDeslanoside may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinDeslanoside may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside.Approved, Vet Approved
TrifluridineDeslanoside may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneDeslanoside may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateDeslanoside may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptorelinDeslanoside may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideDeslanoside may decrease the cardiotoxic activities of Trofosfamide.Investigational
TroleandomycinThe serum concentration of Deslanoside can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinDeslanoside may decrease the cardiotoxic activities of Trovafloxacin.Approved, Withdrawn
TroxacitabineDeslanoside may decrease the cardiotoxic activities of Troxacitabine.Investigational
TTNPBDeslanoside may decrease the cardiotoxic activities of TTNPB.Experimental
TubercidinDeslanoside may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Deslanoside.Approved
TylosinThe serum concentration of Deslanoside can be increased when it is combined with Tylosin.Vet Approved
UbenimexDeslanoside may decrease the cardiotoxic activities of Ubenimex.Experimental
Uracil mustardDeslanoside may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanDeslanoside may decrease the cardiotoxic activities of Vadimezan.Investigational
Val 083Deslanoside may decrease the cardiotoxic activities of Val 083.Investigational
ValrubicinDeslanoside may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibDeslanoside may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideDeslanoside may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
VeliparibDeslanoside may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibDeslanoside may decrease the cardiotoxic activities of Vemurafenib.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
VerteporfinDeslanoside may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneDeslanoside may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineDeslanoside may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineDeslanoside may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineDeslanoside may decrease the cardiotoxic activities of Vindesine.Approved
VinflunineDeslanoside may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineDeslanoside may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideDeslanoside may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibDeslanoside may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin ADeslanoside may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatDeslanoside may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
ZorubicinDeslanoside may decrease the cardiotoxic activities of Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC01AA07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8985
Blood Brain Barrier-0.5781
Caco-2 permeable-0.924
P-glycoprotein substrateSubstrate0.8738
P-glycoprotein inhibitor IInhibitor0.5533
P-glycoprotein inhibitor IIInhibitor0.6189
Renal organic cation transporterNon-inhibitor0.8371
CYP450 2C9 substrateNon-substrate0.8483
CYP450 2D6 substrateNon-substrate0.8905
CYP450 3A4 substrateSubstrate0.7052
CYP450 1A2 substrateNon-inhibitor0.9197
CYP450 2C9 inhibitorNon-inhibitor0.9182
CYP450 2D6 inhibitorNon-inhibitor0.938
CYP450 2C19 inhibitorNon-inhibitor0.9284
CYP450 3A4 inhibitorNon-inhibitor0.9194
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9237
Ames testNon AMES toxic0.9309
CarcinogenicityNon-carcinogens0.9583
BiodegradationNot ready biodegradable0.9845
Rat acute toxicity4.9815 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Inhibitor0.8395
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.468 mg/mLALOGPS
logP-0.49ALOGPS
logP0.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.15ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count9ChemAxon
Polar Surface Area282.21 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity225.65 m3·mol-1ChemAxon
Polarizability100.65 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • 12-hydroxysteroid
  • O-glycosyl compound
  • Glycosyl compound
  • Oxane
  • Saccharide
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Zhao YN, Pan Y, Tao JL, Xing DM, Du LJ: Study on cardioactive effects of brazilein. Pharmacology. 2006;76(2):76-83. Epub 2005 Nov 24. [PubMed:16319518 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23